Moore argues that reports of GLP-1-related muscle loss need more nuance because lean mass includes multiple non-fat tissues and because severe calorie restriction itself reduces lean tissue. She also proposes that reduced fat infiltration can change measured muscle size. Her interpretation does not remove the clinical concern, which is why she emphasizes resistance training and adequate nutrition.

Lean mass is broader than skeletal muscle
Severe calorie restriction can reduce lean tissue regardless of method
Moore distinguishes healthier muscle from fat-infiltrated muscle
She attributes wasting primarily to calorie restriction rather than a direct drug effect
Muscle preservation remains a priority during treatment

“Lean mass is all the soft tissue in your body.”
Dr. Tina Moore · 47:00

“It's the caloric restriction that's causing the wasting.”
Dr. Tina Moore · 49:30

#muscle loss#lean mass#calorie restriction#body composition

Myth Buster52:00

Why the Ozempic–Cancer Discussion Is Not Causal Proof

The host introduces a 2024 observational comparison in which diabetic patients taking Ozempic reportedly had lower bowel-cancer incidence than patients using insulin. Moore notes that insulin is an imperfect comparison and discusses other retrospective associations between GLP-1 treatment and lower obesity-related cancer rates. She explicitly says these findings are correlative, not causative.

The host presents the reported 50% figure as a study finding, not an established effect
Moore says insulin users are not a true control group
She describes other large patient-record analyses as encouraging but observational
Weight loss, metabolic improvement, treatment selection, and other confounders may matter
The episode does not establish that Ozempic prevents cancer

“It's not entirely fair cuz it's not a it's not a true control group”
Dr. Tina Moore · 53:00

“they're correlative, not causative”
Dr. Tina Moore · 53:30

#cancer risk#observational study#correlation#ozempic

Hot Take· 1

Hot Take56:30

GLP-1 Mood Effects May Run in Both Directions

Moore acknowledges reports of suicidal ideation and depression during GLP-1 treatment while arguing that rapid weight loss, hormone changes, loss of food as a coping mechanism, and excessive appetite suppression may contribute. She also reports mood and cognition improvements in her patients. The episode presents a clinical hypothesis and anecdotes, not proof that low dosing prevents psychiatric adverse effects.

Moore does not deny reports of suicidal ideation
She proposes several possible contributors beyond the drug itself
Removing food-based reward or coping can affect mood
She reports improved anxiety, mood, and cognition in her own practice
New or worsening psychiatric symptoms require medical attention

“I'm not saying that people on Ozempic are not having suicidal ideation”
Dr. Tina Moore · 57:00

“if you take that away from someone”
Dr. Tina Moore · 57:30

#mental health#suicidal ideation#appetite suppression#glp-1

Explainer· 5

Explainer02:30

Why Moore Treats the Person, Not Just the Diagnosis

Dr. Tina Moore contrasts her naturopathic approach with the diagnosis-and-standard-treatment model she associates with conventional medicine. She says her goal is to investigate why a person presents with a symptom pattern and to support overall health, while acknowledging that pharmaceuticals can have a place.

Moore describes naturopathic care as focused on causes, resilience, and homeostasis
She says diagnosis matters less to her than the individual's full symptom picture
She combines lifestyle measures with pharmaceuticals when she believes they are useful
Her characterization of conventional medicine is her professional perspective

“I don't treat diseases, I treat people.”
Dr. Tina Moore · 04:30

#naturopathy#root-cause medicine#healthcare

Explainer29:30

What GLP-1 Is and How Semaglutide Mimics It

Moore explains GLP-1 as a peptide signal produced in the gut and brain, while semaglutide is a modified GLP-1 receptor agonist designed to last longer in the body. She highlights effects on appetite, gastric emptying, insulin secretion, and insulin sensitivity.

Peptides are chains of amino acids
The body produces GLP-1 in the gut and brain
Semaglutide is engineered for a longer half-life than endogenous GLP-1
GLP-1 signalling affects appetite and glucose regulation
Effects and risks vary with dose and patient factors

“we are mimicking the actual peptide.”
Dr. Tina Moore · 32:00

“It slows gastric motility, so it slows things down so you feel fuller for longer.”
Dr. Tina Moore · 33:00

#glp-1#semaglutide#peptides#insulin

Explainer43:30

The SELECT Trial Claim—and Its Important Caveats

Moore cites the Novo Nordisk-sponsored SELECT trial as reporting a 20% reduction in severe cardiovascular events among overweight adults without type 2 diabetes. She says a later analysis suggested benefit was not explained only by weight loss. The episode does not provide enough study detail to verify broader claims about tissue regeneration or to generalize the result to microdosing.

Moore identifies Novo Nordisk as the trial sponsor
She reports a 20% reduction in severe cardiovascular events
She says later analysis found benefits independent of the amount of weight lost
The cited trial studied standard semaglutide treatment, not Moore's microdosing protocol
Sponsor, population, dose, and study design matter when applying the result

“Yes, it was sponsored by Novo Nordisk”
Dr. Tina Moore · 44:00

“it showed a 20% reduction in severe cardiovascular events.”
Dr. Tina Moore · 44:00

#select trial#cardiovascular health#clinical evidence#semaglutide

Explainer59:00

Moore's Metabolic View of PCOS and Fertility

Moore links PCOS and some fertility problems to insulin resistance and wider metabolic dysfunction, while also describing environmental and lifestyle factors she believes contribute. She reports seeing PCOS symptoms improve in patients and in her daughter, but the episode does not establish that GLP-1 treatment reverses infertility or PCOS for everyone.

Moore describes PCOS as a metabolic and hormonal pattern, not simply ovarian cysts
She discusses high androgens, low progesterone, and insulin resistance
She believes male and female metabolic health both affect fertility
Her claims about a looming fertility crisis and its causes are broad interpretations
Individual fertility treatment requires specialist assessment

“It's both. It's not just the female's fault, it's not just the male's issue.”
Dr. Tina Moore · 1:01:00

“It's a clinical picture where they have metabolic dysfunction”
Dr. Tina Moore · 1:00:30

#pcos#fertility#metabolic health#hormones

Explainer1:22:00

How GLP-1 Drugs May Quiet Food Noise and Reward Seeking

Moore and the host describe GLP-1 treatment as turning down persistent food thoughts and some reward-seeking behaviour. Moore points to dopamine pathways, animal studies, and patient anecdotes involving alcohol, smoking, cocaine, and shopping, while noting that research is ongoing. These observations do not establish GLP-1 drugs as approved treatments for every addiction discussed.

People often describe reduced food noise rather than simple fullness
Moore links the effect partly to dopaminergic reward pathways
She cites animal findings in which semaglutide changed food preference
She reports anecdotes about reduced alcohol use and compulsive shopping
The addiction applications discussed remain an active research area

“It's quieting the noise.”
Dr. Tina Moore · 1:27:00

“They're studying it”
Dr. Tina Moore · 1:22:30

#food noise#dopamine#addiction#reward seeking

Story· 2

Story11:00

Moore's Family Case Report: Crohn's Disease and Semaglutide

Moore recounts treating her mother during a severe Crohn's disease episode before referring her to another naturopathic physician. Years later, Moore says a very small prescribed amount of semaglutide coincided with improvements in her mother's joint pain, bowel function, cognition, and anxiety. These are family observations reported by the guest, not proof that semaglutide caused or can reproduce those outcomes.

Moore says her mother had severe gastrointestinal illness and a family history of Crohn's disease
Her mother continued other medication under another clinician's management
Moore reports improvements after adding low-dose semaglutide
The account is an anecdotal case report with multiple concurrent treatments

“her naturopathic physician is managing her. So, she's getting medication”
Dr. Tina Moore · 15:00

“Her gut's completely regulated and normalized.”
Dr. Tina Moore · 15:30

#crohn's disease#semaglutide#case report

Story17:30

How Chronic Pain Led Moore Into GLP-1 Research

Moore describes years of gastrointestinal symptoms, anxiety, psoriasis, and severe musculoskeletal pain that she later identified as psoriatic arthritis. After standard elements of her own treatment approach failed to control it, she searched for research connecting GLP-1 signalling with neuroinflammation and began investigating the drug class.

She reports spending much of 2021 unable to stay active because of pain
A psoriasis flare helped her identify psoriatic arthritis as the suspected cause
She searched specifically for GLP-1 and neural inflammation
Her personal response later shaped her clinical interest in low-dose treatment

“nothing that I knew to do was working.”
Dr. Tina Moore · 20:00

“I needed my brain on the case.”
Dr. Tina Moore · 24:00

#chronic pain#psoriatic arthritis#research journey

Q&A· 1

Q&A1:30:00

What We Still Do Not Know About Long-Term Microdosing

The host directly challenges Moore on the absence of long-term clinical studies of GLP-1 microdosing. Moore argues that lower exposure is plausibly less concerning than high doses and discusses gallstones, pancreatitis, bowel obstruction, and gastroparesis, but she does not supply long-term microdosing safety evidence. The exchange leaves efficacy and safety uncertain and reinforces the need for professional prescribing and monitoring.

The host states that long-term microdosing safety has not been clinically established
Moore's lower-dose safety argument is an inference, not direct proof
She identifies biliary disease and rapid weight loss as genuine concerns
Existing illness may alter a patient's baseline risk
The host explicitly rejects unsupervised self-treatment

“we haven't got clinical studies yet to prove that microdosing is safe over the long term”
Steven Bartlett · 1:30:00

“A real concern is biliary disease, so gallstones.”
Dr. Tina Moore · 1:31:30

#safety#microdosing#evidence gaps#adverse effects

Takeaway· 2

Takeaway05:00

Build a Healing State Before Regenerative Treatment

Moore says regenerative injections are less important than first improving the patient's capacity to heal. In her practice, she assessed recovery, hormones, nutrition, and lifestyle before considering prolotherapy, platelet-rich plasma, or stem-cell procedures.

She screened for signs that a patient healed readily from illness or injury
She prioritized hormones, nutrition, and lifestyle before injections
She viewed poor healing as a reason to optimize the patient before proceeding
This reflects Moore's clinical approach, not a universal eligibility rule

“You have to get the person into a healing state first.”
Dr. Tina Moore · 05:30

#healing#regenerative medicine#patient preparation

Takeaway1:53:00

Moore's Closing Rule: Verify the Claim Yourself

Moore closes by urging listeners to remain open-minded while checking sources rather than following influencers or podcast claims uncritically. The host adds that listeners should consult a doctor, inspect the cited studies, and form an independent view, particularly because many ideas in the episode remain hypotheses or anecdotal observations.

Treat confident podcast statements as starting points for investigation
Look for primary sources and study details
Separate hypotheses and anecdotes from established findings
Discuss personal medical decisions with a qualified clinician
Remain willing to revise a position when better evidence arrives

“Don't just follow influencers.”
Dr. Tina Moore · 1:53:30

“everybody listening should do their own research.”
Steven Bartlett · 1:56:00

#critical thinking#evidence#health claims#research

Frameworks in this episode

Clinical Risk-Reward Conversation

Lowest-Effective-Dose GLP-1 Protocol

Muscle-First Metabolic Support Stack

Insights & moments

⚡Myth Buster· 2

Why Lean-Mass Loss Is Not Identical to Muscle Loss